EUVIMEDEUVIMED entdecken
Korrektur

Correction to: Switch to Bictegravir/Tenofovir Alafenamide/Emtrictabine or Dolutegravir + Tenofovir Disoproxil Fumarate/Emtrictabine in Virologically Suppressed People With HIV: Outcomes in Real-world Setting With and Without Tenofovir Resistance

Clinical Infectious Diseases · 13.08.2026

DOI: 10.1093/cid/ciag488 ↗

Kurz gefasst

Korrektur in der Zeitschrift Clinical Infectious Diseases, online erschienen am 13.08.2026.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

(2026). Correction to: Switch to Bictegravir/Tenofovir Alafenamide/Emtrictabine or Dolutegravir + Tenofovir Disoproxil Fumarate/Emtrictabine in Virologically Suppressed People With HIV: Outcomes in Real-world Setting With and Without Tenofovir Resistance. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag488

Vancouver

Correction to: Switch to Bictegravir/Tenofovir Alafenamide/Emtrictabine or Dolutegravir + Tenofovir Disoproxil Fumarate/Emtrictabine in Virologically Suppressed People With HIV: Outcomes in Real-world Setting With and Without Tenofovir Resistance. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag488

BibTeX
@article{euvimed2026,
  title = {Correction to: Switch to Bictegravir/Tenofovir Alafenamide/Emtrictabine or Dolutegravir + Tenofovir Disoproxil Fumarate/Emtrictabine in Virologically Suppressed People With HIV: Outcomes in Real-world Setting With and Without Tenofovir Resistance},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  doi = {10.1093/cid/ciag488}
}
Kostenlos starten →